medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

The role of NIH funding in vaccine readiness; foundational research and NIH funding
underlying candidate SARS-CoV-2 vaccines

Anthony E. Kiszewski,a Ekaterina Galkina Cleary,b,c Matthew J. Jackson,a,b Fred D. Ledleya,b,d,1

a

Department of Natural & Applied Sciences, Bentley University, Waltham, MA 02452; b Center

for Integration of Science and Industry, Bentley University, Waltham MA 02452; c Department
of Mathematical Sciences, Bentley University, Waltham, MA 02452; and d Department of
Management, Bentley University, Waltham, MA 02452.

To whom correspondence should be addressed: fledley@bentley.edu

ORCID ID: Dr. Anthony Kiszewski, orcid.org/0000-0002-7560-1885; Dr. Galkina Cleary,
orcid.org/0000-0002-9384-4020 ; Dr. Jackson, orcid.org/0000-0001-5392-845X; Dr. Ledley,
http://orcid.org/0000-0002-8375-4101.
Author contributions: A.E.K, E.G.C., M.J.J., and F.D.L. designed research; A.E.K, E.G.C.,
M.J.J., and F.D.L performed research; A.E.K., E.G.C., M.J.J., and F.D.L analyzed data; and
A.E.K, E.G.C., M.J.J., and F.D.L. wrote the paper; A.E.K. and F.D.L. supervised the project;
F.D.L. acquired financial support.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1

Address reprint requests to Dr. Ledley at the Center for Integration of Science and Industry,

Bentley University, 175 Forest Street, Waltham, MA, USA 02452 or fledley@bentley.edu.

KEYWORDS
NIH Funding, Vaccine development, COVID-19, SARS-CoV-2

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

ABSTRACT
This work characterizes the NIH contribution to vaccine technologies being employed in
‚Äúwarp speed‚Äù development of vaccines for COVID-19, as well as the lack of sustained NIH
funding for published research against recognized epidemic threats. Using quantitative methods,
we examined the advance of published research on ten of the vaccine technologies incorporated
in the 165 candidate vaccines entering development through July 2020 as well as the NIH
funding that supported this research. Live, attenuated virus, inactivated virus, and adjuvant
technologies have been used in successful products since the 1950s and continue to exhibit
steady advance. Synthetic (recombinant) vaccines, viral vectors, DNA, and TLR9 agonists as
adjuvants emerged since the 1980s, and exhibit a logistic, ‚ÄúS-curve‚Äù pattern of growth
characteristic of emerging technologies that have passed an analytically-defined established
point. In contrast, mRNA, virus-like particle, and nanoparticle technologies show exponential
growth characteristic of technologies short of their established points. The body of research and
NIH funding for established and emerging vaccine technologies exhibited sustained growth
through the late 2010s, supported by >16,000 project years of NIH funding totaling over $17.2
billion (2000-2019), the majority through cooperative agreements and intramural programs. NIH
funding for published research on vaccines for recognized zoonotic threats including
coronavirus, Zika, Ebola, and dengue, however, has been inconsistent and reactive to disease
outbreaks. These data are considered in the context of the high failure rate for candidate vaccines
and evidence that technological maturity is a significant factor in the efficiency of product
development. Sustained funding for both enabling technologies and vaccine development is
essential to ensure a rapid response to COVID and future pandemic threats.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

SIGNIFICANCE STATEMENT
This work examines the advance of research and NIH funding for technologies being
employed in ‚Äúwarp speed‚Äù development of COVID-19 vaccines in the context of evidence that
mature technologies have a greater likelihood of generating successful products. We show that
candidate vaccines for COVID-19 employ a variety of established and still-emerging
technologies, and identify $17.2 billion in NIH funding for this research from 2000-2019. In
contrast, NIH funding for published research for vaccines on recognized pandemic threats has
been inconsistent. This work highlights the significance and scale of the NIH contribution to
vaccine technologies and the lack of sustained initiatives for vaccine development.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

INTRODUCTION
The COVID-19 pandemic has triggered an unprecedented mobilization of global vaccine
development efforts. With fatality rates approaching or exceeding 1% (Basu, 2020), the prospect
of long-term sequelae in those who recover (Demertzis et al., 2020; Fiani et al., 2020), and the
high level of population immunity required to halt transmission (Flaxman et al., 2020), initiatives
are expected to proceed at ‚Äúwarp speed‚Äù (O‚ÄôCallaghan, Blatz, & Offit, 2020; Corey et al., 2020).
Within six months of the first description of the SARS-CoV-2 virus (Zhu et al., 2020), a wide
variety of vaccine candidates entered clinical development (WHO, 2020). Many were based on
platforms such as attenuated or inactivated virus, synthetic (recombinant) proteins, and
conventional adjuvants that have already been used in successful vaccines for diseases such as
influenza or polio. Some exploited technologies previously shown to generate immune responses
against other human coronaviruses, including Middle East Respiratory Syndrome virus (MERSCoV) (Modjarrad, 2016) and SARS-CoV-1 (McPherson et al., 2016). Some incorporated
technologies utilized in vaccines registered for veterinary use against animal coronaviruses such
as Infectious Bronchitis Virus (IBV) (Li et al., 2018) and bovine Betacoronavirus-1 (Decaro et
al., 2009). Others incorporated novel technologies, such as recombinant viral vectors, DNA, or
mRNA, which have not yet demonstrated safety and efficacy in humans.
Vaccine development remains daunting on several fronts despite a vaunted history that
includes the global eradication of smallpox, the near elimination of polio (Plotkin, 2014), the
emergence of effective vaccines for seasonal influenza, common childhood diseases, and many
other viral and bacterial pathogens. Evidence suggests a failure rate of 94% for vaccines entering
clinical development, and that, for successful products, the timeline from preclinical studies to

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

approval is 10.7 years (Pronker et al., 2013). There are a number of reasons for this high failure
rate and prolonged developmental timeline.
First, many pathogens have been refractory to vaccine development. High mutation rates
render HIV a moving target (Safrit et al., 2016), while influenza undergoes rapid evolution
through both antigenic shift and drift (Kim, Webster, & Webby, 2018). Strain differences trigger
adverse immune responses with dengue virus (WHO, 2018), and extreme diversity and immunoevasive adaptions have complicated development of vaccines for malaria parasites (Laurens,
2018). Prior sensitization to non-TB bacterial antigens reduce the BCG vaccine‚Äôs impact on
tuberculosis (Arregui et al., 2016).
Second, some vaccine development challenges are platform-based and independent of the
target. Adverse activation of and interference by Type I interferon has plagued the development
of RNA-based vaccines (Pardi et al., 2018; De Beuckelaer et al., 2016). DNA-based vaccines are
prone to insufficient stimulation of immunity (Porter & Raviprakash, 2017).
Third, development of public health vaccines is classically challenged by issues of cost,
stability, and safety. The market for public health vaccines is extremely cost-sensitive given
limited public health budgets, the reliance of many regions on non-governmental organizations
such as UNICEF or PAHO to purchase vaccines, and the need to vaccinate large numbers of
people (Randolph & Barreiro, 2020) to achieve community protection. Moreover, many vaccine
technologies produce thermally unstable products requiring refrigeration in lieu of rapid
administration. This can dramatically increase distribution costs or render widespread use
impractical (Kristensen et al., 2016).

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Fourth, given the intense scrutiny of vaccine safety in light of misleading claims and public
skepticism of vaccines fomented by the anti-vax movement, widespread public acceptance will
require developers to demonstrate an exemplary margin of efficacy and safety (Ball, 2020).
Finally, it should be noted that general public health measures can also be effective against
pandemic disease, and the rapid dissipation of outbreaks related to viruses such as SARS-CoV-1
and Zika have made thorough clinical validation of vaccines impossible (Thomas & Barrett,
2020).
This work is predicated on innovation research across many different fields demonstrating
how the maturation level or readiness of a technology is a critical determinant in its ability to
generate products that successfully meet market needs (Christensen, 1992; Christensen, 1997;
GAO 1999; Clausing & Holmes, 2010; Foster, 1982; McNamee & Ledley, 2012). Our previous
work has explored the applicability of this principle to drug development using a bibliometric
model for the maturation of basic, biomedical research on novel drug targets or therapeutic
modalities based on the rate of publication (McNamee, Walsh, & Ledley, 2017). Studies on the
development of more than 500 approved drugs have shown that few targeted therapeutics are
successfully developed before research on both the drug target and the therapeutic modality have
passed an analytically derived established point, and that the timelines of development are
significantly shorter when clinical trials commence after this point (Beierlein et al., 2017,
McNamee & Ledley, 2017, McNamee, Walsh, & Ledley, 2017, Ledley et al., 2014, Cleary,
Jackson, & Ledley, 2020).
Additional studies have examined the scale of NIH funding for this body of enabling, basic
research (Cleary et al., 2018; Cleary, Jackson, & Ledley, 2020). These studies show that the NIH
contributed more than $230 billion in funding for research related to the 356 drugs approved

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

from 2010‚Äì2019 or their 218 drug targets. Significantly, more than 85% of this funding was
categorized as basic research on the drug targets, rather than research on the drugs themselves.
The present work examines the maturation of the technologies employed in current efforts to
develop COVID-19 vaccines. Specifically, we examine the timelines of published research on
technologies related to adjuvants, recombinant proteins, nucleic acids, attenuated/inactivated
virus, viral vectors, and formulations using virus-like particles or nanoparticles, the maturity of
this research at the end of 2019, and the NIH funding that contributed to this research. We also
examine the timelines of research directed towards vaccines for coronaviruses and three
unrelated viral pathogens that have been associated with epidemic transmission (Zika, Ebola, and
dengue). We consider the impact of this prior research on accelerated efforts to develop a
vaccine for COVID-19, and the importance of sustained public sector funding in establishing a
foundation for responding to pandemic outbreaks.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

RESULTS
Research on vaccine technologies
As of July 31, 2020, the WHO listed 165 candidate vaccines against COVID-19: six in Phase
3 trials, twenty in Phase 1 and/or 2, and 139 in various stages of preclinical development (WHO,
2020). PubMed searches were performed for ten prevalent vaccine technologies from the
portfolio of products described in the WHO report. The technologies examined and number of
research publications related to each topic are shown in Table 1. Cumulative publications over
time are shown in Figure 1A.
Several viral technologies involving whole virus preparations, including live/attenuated and
killed/inactivated viral vaccines, as well as non-specific adjuvants, predate the modern era. These
are used in classical vaccines including polio, influenzas, MMR, and others that emerged as
prominent elements of public health in the 1950s. Research on these technologies has
accumulated steadily since 1980 (Figure 1A). Inactivated viral approaches accounted for four of
the first ten candidate vaccines to enter human clinical trials against COVID-19, but only 12
(7.3%) candidate vaccines as of July 31, 2020.
Synthetic vaccines employing recombinant protein subunits emerged in the 1980s,
capitalizing on the advances in large-scale protein production and purification. Exponential
growth of research on synthetic vaccines was evident after 1985 followed by steady growth from
the mid-1990s to the present time (Figure 1A). While only one of the first ten COVID-19
candidate vaccines to enter clinical trials employed these technologies, recombinant protein
antigens are incorporated in 66 (40%) of candidate vaccines as of July 31, 2020.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Vaccines based on recombinant viral vectors that express immunogens emerged in the mid1990s as an outgrowth of research on gene therapy and experienced a period of exponential
growth and subsequent slowing from the early 2000s to the present (Figure 1A). Two of the first
ten COVID-19 candidate vaccines to enter human trials were based on recombinant adenoviral
vectors. Other vaccines currently in clinical development use other viral vectors, including VSV,
measles, Sendai virus, avian paramyxovirus, baculovirus, lentivirus, and influenza. Overall, viral
vectors are employed in 31 (19%) candidate vaccines.
DNA-based vaccine technologies emerged in the mid-1990s, also as an outgrowth of research
on gene therapy, and exhibited a period of rapid acceleration and subsequent slowing. These
technologies involve injection of plasmid or synthetic DNA molecules, with the expectation that
the injected DNA will be taken up by cells in the body and express the antigen.
A related nucleic acid-based approach involves direct injection of mRNA, which cells take up
and translate into antigenic proteins. This approach derives from early methods for expressing in
vitro translated mRNA in Xenopus oocytes, and production of infectious virus through injection
of purified viral mRNA into cultured cells (Schlake et al., 2012). This field has exhibited steady
growth with the emergence of advanced nucleotide chemistries, self-replicating mRNA, and
improved delivery methods.
One DNA vaccine and two mRNA vaccines were among the earliest candidate vaccines to
enter human trials. Both mRNA vaccines were among the first to enter Phase 3 clinical
evaluation. Overall, there were 36 (22%) nucleic acid-based vaccines in development as of July
31, 2020, 14 based on DNA and 22 with RNA.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Several other vaccine technologies currently employed in candidate COVID-19 vaccines are
also shown in Figure 1A, including lipid nanoparticles and virus-like particles designed to
enhance delivery and antigenicity of recombinant proteins as well as the use of novel adjuvants
(i.e., toll-like receptor 9 [TLR9] agonists) designed to stimulate specific immune pathways.
These technologies were employed in 24 (15%) of the 165 candidate vaccines under
development on July 31, 2020.
The maturity of the seven technologies emerging since 1980 was examined using the
Technology Innovation Maturation Evaluation (TIME) model (Figure 1B). This model fits the
cumulative number of publications to an exponentiated logistic function. Plotted on a log scale,
this function exhibits the logistic ‚ÄúS-curve‚Äù that is characteristic of technology growth in many
different fields, including drug development (Foster, 1982; Christensen, 1992; Christensen,
1997; McNamee & Ledley, 2012; McNamee, Walsh, & Ledley, 2017). From this equation, it is
possible to calculate the initiation point of research on each topic (defined as the point of
maximum acceleration) and the established (Te) point (defined as the point of maximum
deceleration) (Figure 1B). Individual curve fits are shown in Supplemental Figures 1, 2, and 3.
Four technologies (synthetic, DNA, viral vector, and TLR9 agonists) exhibited a logistic
pattern of growth characteristic of maturity (Figure 1B). Each of these technologies passed their
established point prior to 2010. Three technologies (virus-like particles, mRNA, and
nanoparticles) did not exhibit a logistic pattern of growth with clear evidence of maximal
deceleration. This pattern is characteristic of technologies that have not yet passed their
established point.
NIH funding for published research on vaccine technologies

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

The NIH RePORTER database was used to identify published research (via PMID)
acknowledging NIH funding support, specific projects and project years associated with these
publications, and the project costs for those years. The total numbers of PMID, number and
percent NIH-funded PMID, project years, and project costs for ten vaccine technologies are
shown in Table 1. We identified a total of 51,530 publications related to these ten vaccine
technologies, including 8,420 (16%) associated with NIH funding, comprising 16,358 project
years and $17.2 billion in project costs. The NIH contributed the most funding for synthetic
(recombinant) vaccines ($9.65 billion) followed by adjuvant research ($5.6 billion), DNA
vaccines ($4.6 billion), and live, attenuated virus ($4 billion). More than $1 billion in NIH
funding was associated with research on inactivated virus and viral vector-based vaccines as well
as TLR9 agonists as adjuvants. More than $500 million was invested in mRNA vaccines, viruslike particles, and nanoparticle-based vaccines combined.
The annual number of publications, NIH-funded publications, project years, and project costs
for the ten technologies are shown in Figures 2A-B. The annual totals for each technology
individually are shown in the interactive graphic https://tabsoft.co/31EkYeK. Publication activity
increased steadily from 1980 to 2010, with the fraction of publications acknowledging NIH
funding rising from 4% in 1980 to 20% in 2010. After 2010, annual publications and the fraction
of NIH-funded publications both decreased. The number of NIH project years and costs similarly
increased from 2000‚Äì2010, and have decreased considerably in recent years.
The activity code categories for NIH projects associated with published research on vaccine
technologies are shown in Figure 3A. While 40% of project years associated with research on
these technologies represented investigator-initiated research projects, these accounted for only
8.9% of the total project costs. A greater fraction of funding was associated with cooperative

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

agreements (44%), intramural programs (9.4%), and research program projects and centers
(22.7%). This pattern differs sharply from that seen for development of new drugs approved
from 2010‚Äì2019 (Cleary, Jackson, & Ledley, 2020), where the majority of project years and
funding for research on drug targets was associated with investigator-initiated research projects.
However, this pattern does resemble that of molecular research underlying the discovery and
development of remdesivir for treatment of COVID-19 (Cleary, Jackson, Folchman-Wagner &
Ledley, 2020).
Research and NIH funding for diseases with pandemic potential
Table 1 shows the number of PMID, NIH-funded PMID, project years, and project costs
associated with vaccine development for HIV, which has been the subject of intensive vaccine
research since the 1980s, as well as Ebola, Zika, dengue, and coronavirus. Figure 4A shows the
timeline of combined NIH project costs for these four viruses since 2000 compared to the project
costs for research on HIV vaccines. NIH funding for research on HIV vaccines increased more
than fourfold from 2000‚Äì2014, and has subsequently declined. There was little NIH funding for
research on Ebola, Zika, dengue, or coronaviruses prior to 2014.
Figure 4B shows the annual project costs for vaccine research on Ebola, Zika, dengue, and
coronaviruses individually. The annual totals for PMID, NIH-funded PMID, projectyears and
projects costs for research related to each virus is shown in the interactive graphic
https://tabsoft.co/31EkYeK. NIH funding associated with publications on vaccines for Ebola
virus exhibited a sharp peak in 2009, a larger peak from 2013‚Äì15, and another resurgence in
2019. These peaks corresponded to a relatively small outbreak of Ebola in 2007, the major
outbreak in 2014, which had limited spread to Europe and the US, and an ongoing event that
began in 2018 (https://www.cdc.gov/vhf/ebola/history/chronology.html).

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

A single peak of NIH funding associated with publications related to vaccines for Zika was
evident, corresponding to the 2015‚Äì17 outbreak in South America and the Caribbean that also
impacted several US states. Another funding peak was evident following the outbreak of SARSCoV-1 in Asia and its subsequent spread to Toronto. A rise in funding for publications related to
dengue was apparent in 2016, coincident with recognition of the increasing prevalence of this
disease, but dropped rapidly coincident with an abrupt decrease in reported cases in 2017 and
2018 (https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue). These data
indicated a lack of sustained NIH funding for vaccine research in the wake of waning disease
outbreaks.
The pattern of NIH funding for published research on coronavirus vaccines shows a similar
lack of sustained funding and research activity. NIH project costs associated with published
research on coronaviruses peaked in 2005, then dropped steadily to 2013. A second peak of NIH
funding associated with published research on coronavirus vaccines was evident following the
MERS outbreak in 2012, which peaked in 2015 and then declined rapidly.
Figure 3B shows the activity code categories for the NIH projects associated with published
research on coronavirus vaccines. While the majority of project years were associated with
investigator-initiated research projects, only 14% of project costs were associated with research
projects, while 34% went to cooperative agreements, 26% to intramural programs, and 22% to
research program projects and centers. Thus, as with NIH funding for research on vaccine
technologies, the majority of project costs came through research organized or conducted by
government agencies, rather than from investigator-initiated projects.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

DISCUSSION

This analysis was undertaken in the context of research showing that there is a 94% failure
rate for vaccines entering development (Pronker et al., 2013). The exigency for ‚Äúwarp speed‚Äù
development of a COVID-19 vaccine to stem the ongoing pandemic (O‚ÄôCallaghan, Blatz, &
Offit, 2020; Corey et al., 2020), and evidence that maturity of the underlying technologies is a
significant factor in the efficiency of biopharmaceutical development (McNamee, Walsh, &
Ledley, 2017; Cleary, Jackson, & Ledley, 2020). Using quantitative methods, we examine
published research on ten technologies that are being used in candidate vaccines for COVID-19
and estimate the maturity, or readiness, of these technologies for clinical development. We also
describe the NIH contribution to development of these technologies through the end of 2019, as
well as support for vaccine development directed towards specific zoonotic threats like
coronavirus, Zika, Ebola, and dengue.
Some of the technologies used by COVID-19 candidate vaccines (live attenuated or
inactivated virus, non-specific adjuvants) date from the mid-20th century and have been used to
create many successful vaccine products. While we found that the research literature on these
technologies continues to grow, there is no evidence of exponential acceleration since 1980,
suggesting that these technologies had become well-established before that time.
Research on synthetic (recombinant) vaccines, DNA vaccines, (recombinant) viral vectors,
and TLR9 agonist-based adjuvants exhibited an ‚ÄúS-curve‚Äù pattern of publication activity when
fitted to the TIME model. Their curves‚Äô inflection points suggest that each of these technologies
was established prior to 2010. In contrast, three technologies‚ÄîmRNA vaccines, virus-like

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

particles, and nanoparticles‚Äîexhibit exponential patterns of growth through 2019, suggesting
these technologies have not yet reached their established point.
It should be emphasized that the TIME model does not attempt to identify singular
publications representing significant milestones in vaccine development. Rather, the model
posits that the complete body of published research describing original insights or inventions, the
replication or refinement of previous observations, and/or refutation of erroneous results all
contribute to the foundation of knowledge required for efficient product development.
Previous research using the TIME model has demonstrated a relationship between metrics of
technology maturation and the efficiency of development. Studies of drug development for
cancer (McNamee & Ledley, 2017) and cardiovascular disease (Beierlein et al., 2017)
demonstrate that few new drugs were approved before research on the biological target or class
of drugs passed the established point. Similarly, approvals were rare for products utilizing
monoclonal antibodies (McNamee & Ledley, 2012), nucleotide therapeutics (Beierlein,
McNamee, & Ledley, 2017), and gene therapies (Ledley et al., 2014) before research on these
modalities passed the established point. Moreover, the timeline of clinical development from
Phase 1 to approval is significantly shorter when clinical trials commence after the underlying
technologies have passed this point (McNamee, Walsh, & Ledley, 2017; Cleary, Jackson, &
Ledley, 2020; Beierlein et al., 2017). These observations are consistent with studies of
technological innovation in other sectors, which show that nascent technologies are commonly
unable to meet the standards required by established markets, despite the fact that these
technologies offer potential advantages and may ultimately supplant incumbent technologies in
the marketplace (Christensen, 1992; Christensen, 1997; McNamee & Ledley, 2012).

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Experience with vaccine development offers many parallels. The success of the Salk vaccine
was preceded by several unsuccessful efforts to develop inactivated or attenuated viral vaccines.
Moreover, the roll-out of the Salk vaccine itself was complicated by an outbreak of polio caused
by inadequate inactivation of early batches of the product, which led to temporary suspension of
the vaccine program months after the vaccine was approved (Blume, 2005). Similarly, early
versions of both RSV and Measles vaccines were associated with enhanced disease on reexposure, reflecting the immature knowledge of vaccines and the immune system in that era
(Lambert et al., 2020). More recently, a dramatic decline in the success rate for vaccine
development from 2003‚Äì2013 has been ascribed, in part, to the repeated failures of then-nascent
DNA technologies and unresolved problems with immunogenicity (Stephens, 2014). In contrast,
the remarkable safety of vaccines currently approved by the FDA (Tau, Yahav, &
Shepshelovich, 2020), as well as the annual development of seasonal influenza vaccines for
emerging strains of influenza virus, are consistent with the efficiency of established vaccine
technologies.
This pattern is incorporated in an economic model of vaccine development prepared for the
Coalition for Epidemic Preparedness Innovations (CEPI), in which vaccine technologies having
‚Äúno licensure track-record‚Äù are assumed to be associated with a greater risk of vaccine failure
and higher development costs than ‚Äúwell-established‚Äù technologies (Gouglas et al., 2018). The
CEPI model estimates the failure rate of vaccines in development is greater than 90%, and the
cost of developing a vaccine from preclinical through Phase 2a (entry of Phase 3) to be between
$137 million and $1.1 billion. This wide range reflects, in part, differences in the cost of
development for technologies without, or with, a track record of licensure, as well as variations
in indirect cost (Gouglas et al., 2018).

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

In this context, the over-representation of mRNA-based vaccines among the leading COVID19 candidate vaccines is of some concern given the relative immaturity of these technologies as
measured by the TIME model. Nucleic acid-based vaccines were able to move more rapidly into
clinical trials (WHO, 2020) due to inherent efficiencies in process development and scale up of
production of these products. This analysis suggests that there may be substantially more
downstream risk of product failure or delay with such immature technologies.
We would also note that there is no licensure track record for adenoviral vaccines, which were
also able to rapidly enter clinical trials and progress through the initial development stages. Prior
to the emergence of COVID-19, two MERS vaccines utilizing these technologies passed Phase 1
trials before the waning of these diseases precluded further testing (Modjarrad et al., 2019;
Folegatti et al., 2020).
The cost of vaccine discovery and development typically relies on both public and private
sector investments. A 1997 report by the National Vaccine Advisory Committee concluded that
‚Äútwo thirds of all new vaccines provided worldwide have been produced by a US network of
independent industrial, governmental, and academic partners engaged in vaccine research and
development‚Äù (NVAC, 1997). A 2001 report by the World Bank, working with Gavi, the
Vaccine Alliance, described the role of public sector institutions as being primarily focused on
basic science ‚Äúmeasured by the number and value of the research manuscripts they publish in the
scientific literature‚Äù (Batson & Bekier, 2001; Francis, 2010). In contrast, industry focused on
development, manufacture, and marketing of vaccine products (Batson & Bekier, 2001), and
more than 90% of all vaccine doses procured in the past five years have been manufactured by
for-profit organizations (WHO, 2019).

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

We also examined NIH funding related to four diseases with recognized epidemic potential
including coronavirus, Zika, Ebola, and dengue. The first three were identified by the WHO as
pandemic risks in the 2016 ‚ÄúR&D Blueprint for Action to prevent Epidemics‚Äù (WHO, 2016) and
have been identified as priority epidemic infectious diseases by CEPI (Gouglas et al., 2018).
Dengue is an endemic pathogen that causes focal outbreaks, which was considered to be outside
the scope of the 2016 Blueprint (Mehand et al., 2018).
A lack of sustainable investment has long been recognized as a limiting factor in developing
vaccines for emergent pandemic threats, particularly those initially impacting low-income
countries (Rappuoli, Black, & Bloom, 2019). This problem is exacerbated by the fact that
vaccine development typically requires coordinated and sustained funding for research
encompassing immunization technologies, disease pathogens, vaccine formulation, and clinical
development.
Our analysis describes a sporadic pattern of grant funding related to coronavirus, Zika, Ebola,
and dengue viruses, in which outbreaks of disease trigger an increase in grant-funded publication
activity, which then wanes rapidly over several years. This is consistent with the observation that
investigator-initiated grant mechanisms have not proved to be a robust mechanism for vaccine
development (Rappuoli, Black, & Bloom, 2019).
Our work also demonstrates that while the largest fractions of PMIDs and project years
represented investigator-initiated research projects, a majority of the funding was associated with
government-initiated research through cooperative agreements or intramural research, or for
research capacity through research program projects and centers. This pattern has been observed
previously in examining the foundational research underlying development of remdesivir
(Cleary, Jackson, Folchman-Wagner, & Ledley, 2020). This pattern, however, is distinctly

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

different from that of NIH funding associated with drugs in other therapeutic areas, where the
large majority of research funding involves investigator-initiated research projects or related
research program projects and centers (Cleary, Jackson, & Ledley, 2020). Further research is
required to understand the determinants of investigator-initiated versus government-initiated
research, and how these different mechanisms contribute to the development of vaccine
technologies and vaccines for pandemic threats.
Finally, we would note that there is no demonstrated relationship between the amount of NIH
funding and the success of vaccine development initiatives. Despite decades of research and
billions of dollars in NIH funding, vaccines have yet to be registered for diseases such as HIV
and hepatitis C. In contrast, the NIH contributed little funding to published research on Ebola or
dengue viruses, both of which are associated with FDA-approved vaccines.
Limitations of this research
There are several important limitations to this study. First, this analysis is restricted to
research that produces publications in PubMed, which may not capture research described in
white papers, reports, patents, regulatory filings, unpublished clinical studies, or trade secrets.
This method may also fail to identify publications describing enabling technologies not directly
related to vaccines, early research performed before accepted vocabularies emerge, and
publications without abstracts in PubMed. Second, it is not possible to associate costs with every
NIH-funded publication due to missing data in RePORTER and inconsistencies between
publication dates and project years. Moreover, given an estimated lag of up to three years
between research funding and publication (Boyack & Jordan, 2011), funding for research
performed since 2018 may be underrepresented in the data collection. Third, this analysis does
not account for research funded by agencies outside HHS, particularly DOD or NSF, government

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

contracts, other nations, philanthropies, or academic institutions. Nor does it account for the $1.8
billion that the U.S. contributed to Gavi since 2009 (KFF, 2020) or for investments by industry
in clinical trials of process development.
Conclusion
The ‚ÄúOperation Warp Speed‚Äù and ‚ÄúAccelerating COVID-19 Therapeutic Interventions
and Vaccines (ACTIV)‚Äù initiatives involved funding a variety of different candidate vaccines
utilizing different technologies. This work demonstrates that the technologies represented in this
portfolio vary significantly in maturity. Inasmuch as technological maturity is often a significant
factor in the efficiency and cost of product development, the maturity of individual technologies
should be a factor in guiding both expectations for success and investment in different candidate
vaccines.
This work highlights the scale and importance of a broad, sustained foundation of NIH
funding in the ability to respond to the COVID-19 pandemic. The research that will enable rapid
development of a COVID-19 vaccine was not undertaken with such a vaccine in mind, but was
often undertaken in unrelated contexts such as basic molecular biology, gene therapy,
immunology, or drug delivery. Nevertheless, this funding advanced the maturation of
technologies that are now available for application in COVID-19 vaccines. Significantly, the
majority of this funding came in the form of government-initiated cooperative agreements or
intramural research, rather than investigator-initiated research projects.
In contrast, this work again demonstrates the lack of sustained research and NIH funding
related to recognized, epidemic threats, such as coronavirus, may have contributed to the lack of
preparedness for the emergence of COVID-19. Further consideration needs to be given to the

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

mechanisms of funding research on emerging pandemic threats beyond coronavirus (WHO,
2016) to ensure that the technologies are ready to respond.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

METHODS
Technologies utilized in candidate vaccines against COVID-19 were identified from the WHO
‚ÄúDRAFT Landscape of Candidate COVID-19 vaccines‚Äù (WHO, 2020) accessed July 31, 2020.
Viruses with epidemic potential that have been subject to intensive vaccine development
initiatives were identified from Plotkin, 2017, and the WHO Blueprint (Plotkin 2017; Mehand et
al., 2018).
Searches were performed in PubMed (www.pubmed.gov; accessed June 3, 2020) using the
updated Automatic Term Mapping (May, 2020), initially with Medical Subject Headings
(MeSH) terms, and then optimized with Boolean modifiers to increase specificity. PubMed
Identifiers (PMIDs) and publication year were recorded for each publication identified.
We then quantified the contribution of NIH funding to publications identified in PubMed
using NIH RePORTER (https://exporter.nih.gov/ExPORTER_Catalog.aspx; accessed June 3,
2020) via methods reported in a similar study of drug development (Cleary et al., 2018). A
tabulation of NIH-sponsored research that led to these publications was derived from the
RePORTER/ExPORTER format files catalog (NIH, 2020). Wherever possible, each PMID was
associated with a project year corresponding to the project number and fiscal year in the ‚ÄúLink
Tables for Project to Publication Associations.‚Äù The ‚ÄúProject Data Table‚Äù provided the fiscal
year costs for each project (since 2000). Costs were derived for each project year corresponding
to the program cost associated with PMIDs via the Project Table. Activity codes associated with
the core project indicated the type of grant.
Publications occurring before the first year of the grant award or more than four years after the
last year of the grant were excluded. Publications 1‚Äì4 years after the last year of the grant were

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

associated with the project costs of the last year. Grant categories were derived from ‚ÄúNIH Types
of Grant Programs 2020‚Äù (https://grants.nih.gov/grants/funding/funding_program.htm; accessed
May, 2020). Costs are given in constant dollars inflation adjusted to 2018 using the U.S. Bureau
of Labor Statistics All Urban Consumer Prices (Current Series) (https://www.bls.gov/data/;
accessed May, 2020). All analyses were performed in PostgreSQL and Excel.
The relative maturity of seven critical technologies emerging since 1980 was examined by
fitting the bibliographic Technology Innovation Maturation Evaluation (TIME) model, an
exponentiated logistic function described previously, to a time series of publication records
derived from PubMed searches (McNamee, Walsh, & Ledley, 2017). The equation has the form:
 

 



‡∞∑‡≥ù·à∫‡≥ü‡∞∑‡≥ü‡∞¨ ·àª

Where N is the number of publications, L is the presumed upper limit of publications, r is the
growth rate, t is time, and t0 is midpoint of the exponential growth. This asymmetric sigmoidal
function exhibits the common logistic sigmoid function over log scales. The parameters were fit
to time-series publication data using a non-linear least squares implementation of the LevenbergMarquardt algorithm (LMFIT, version 1.0.1).
The initiation and established points, representing the beginning and end of the exponential
growth phase are defined as the points of maximum and minimum acceleration respectively, or
logN‚Äô‚Äô(t)max,min. These points are analytically determined by:




,  

    






medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

ACKNOWLEDGEMENTS
This work was supported by a grant from the National Biomedical Research Foundation to
Bentley University. The authors thank Prateet Shah for his contributions to this manuscript as
well as Drs. Michael Boss and Nancy Hsiung for their constructive suggestions.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

REFERENCES
Arregui, Sergio, Sanz, Joaqu√≠n, Marinova, Dessislava, Mart√≠n, Carlos, and Moreno, Yamir. 2016.
On the impact of masking and blocking hypotheses for measuring the efficacy of new
tuberculosis vaccines.‚Äù PeerJ 4:e1513. doi: 10.7717/peerj.1513
Ball, P. 2020. ‚ÄúAnti-vaccine movement could undermine efforts to end coronavirus pandemic,
researchers warn.‚Äù Nature. doi: 10.1038/d41586-020-01423-4.
Basu, Anirban. 2020. ‚ÄúEstimating the infection fatality rate among symptomatic Covid-19 cases
in the United States: Study estimates the COVID-19 infection fatality rate at the US
county level.‚Äù Health Affairs https://doi.org/10.1377/hlthaff.2020.00455
Batson, Amie and Bekier, Matthias M. 2001. ‚ÄúVaccines where they're needed.‚Äù The McKinsey
Quarterly. Autumn 2001..
Beierlein, Jennifer M, McNamee, Laura M., and Ledley, Fred D. 2017. ‚ÄúAs technologies for
nucleotide therapeutics mature, products emerge.‚Äù Molecular Therapy-Nucleic Acids
9:379‚Äì386.
Beierlein, Jennifer M, McNamee, Laura M., Walsh, Michael J., Kaitin, Kenneth I., DiMasi,
Joseph A., and Ledley, Fred D. 2017. ‚ÄúLandscape of innovation for cardiovascular
pharmaceuticals: From basic science to new molecular entities.‚Äù Clinical Therapeutics 39
(7):1409‚Äì1425.
Blume, Stuart S. 2005. ‚ÄúLock in, the state and vaccine development: Lessons from the history of
the polio vaccines.‚Äù Research Policy 34 (2):159‚Äì173.
Boyack, Kevin W. and Jordan, Paul. 2011. ‚ÄúMetrics associated with NIH funding: A high-level
view.‚Äù Journal of the American Medical Informatics Association 18 (4):423‚Äì431.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Christensen, Clayton M. 1992. ‚ÄúExploring the limits of the technology Scurve. Part I:
component technologies.‚Äù Production and Operations Management 1 (4):334‚Äì357.
Christensen, Clayton M. 1997. The Innovator's Dilemma: When New Technologies Cause Great
Firms to Fail. Boston, MA: Harvard Business School Press.
Clausing, Don and Holmes, Maurice. 2010. ‚ÄúTechnology readiness.‚Äù Research-Technology
Management 53 (4):52‚Äì59.
Cleary, Ekaterina Galkina, Beierlein, Jennifer M., Khanuja, Navleen Surjit, McNamee, Laura
M., and Ledley, Fred D. 2018. ‚ÄúContribution of NIH funding to new drug approvals
2010‚Äì2016.‚Äù Proceedings of the National Academy of Sciences 115 (10):2329‚Äì2334.
Cleary, Ekaterina Galkina, Jackson, Matthew J., Folchman-Wagner, Zoe, and Ledley, Fred D.
2020. Foundational research and NIH funding enabling Emergency Use Authorization of
remdesivir for COVID-19.‚Äù medRxiv.
www.medrxiv.org/content/10.1101/2020.07.01.20144576v1
Cleary, Ekaterina Galkina, Jackson, Matthew J., and Ledley, Fred D. 2020. ‚ÄúGovernment as the
First Investor in Biopharmaceutical Innovation: Evidence From New Drug Approvals
2010‚Äì2019.‚Äù INET Economics Working Paper Series, September 2020.
www.ineteconomics.org/research/research-papers/government-as-the-first-investor-inbiopharmaceutical-innovation-evidence-from-new-drug-approvals-2010-2019
Corey, Lawrence, Mascola, John R., Fauci, Anthony S., and Collins, Francis S. 2020. ‚ÄúA
strategic approach to COVID-19 vaccine R&D.‚Äù Science 368 (6494):948‚Äì950.
De Beuckelaer, Ans, Pollard, Charlotte, Van Lint, Sandra, Roose, Kenny, Van Hoecke, Lien,
Naessens, Thomas, Udhayakumar, Vimal Kumar, Smet, Muriel, Sanders, Niek, and
Lienenklaus, Stefan. 2016. ‚ÄúType I interferons interfere with the capacity of mRNA

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

lipoplex vaccines to elicit cytolytic T cell responses.‚Äù Molecular Therapy 24 (11):2012‚Äì
2020.
Decaro, Nicola, Campolo, Marco, Mari, Viviana, Desario, Costantina, Colaianni, Maria
Loredana, Di Trani, Livia, Cordioli, Paolo, and Buonavoglia, Canio. 2009. ‚ÄúA candidate
modified-live bovine coronavirus vaccine: Safety and immunogenicity evaluation.‚Äù The
New Microbiologica 32 (1):109-113.
Demertzis, Zachary D., Dagher, Carina, Malette, Kelly M., Fadel, Raef A., Bradley, Patrick B.,
Brar, Indira, Rabbani, Bobak T., and Suleyman, Geehan. 2020. ‚ÄúCardiac Sequelae of
Novel Coronavirus Disease 2019 (COVID-19): A Clinical Case Series.‚Äù European Heart
Journal-Case Reports doi.org/10.1093/ehjcr/ytaa179.
Fiani, Brian, Covarrubias, Claudia, Desai, Aditi, Sekhon, Manraj, and Jarrah, Rayan. 2020. ‚ÄúA
contemporary review of neurological sequelae of COVID-19.‚Äù Frontiers in Neurology
11:640.
Flaxman, Seth, Mishra, Swapnil, Gandy, Axel, Unwin, H., Coupland, Helen, Mellan, T., Zhu,
Harisson, Berah, Tresnia, Eaton, J., and Guzman, P. Perez. 2020. ‚ÄúReport 13: Estimating
the number of infections and the impact of non-pharmaceutical interventions on COVID19 in 11 European countries.‚Äù www.imperial.ac.uk/mrc-global-infectious-diseaseanalysis/covid-19/report-13-europe-npi-impact/.
Folegatti, Pedro M., Bittaye, Mustapha, Flaxman, Amy, Lopez, Fernando Ramos, Bellamy,
Duncan, Kupke, Alexandra, Mair, Catherine, Makinson, Rebecca, Sheridan, Jonathan,
and Rohde, Cornelius. 2020. ‚ÄúSafety and immunogenicity of a candidate Middle East
respiratory Ssyndrome coronavirus viral-vectored vaccine: A dose-escalation, open-label,

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

non-randomised, uncontrolled, Phase 1 trial.‚Äù The Lancet Infectious Diseases
doi.org/10.1016/S1473-3099(20)30160-2,
Foster, Richard N. 1982. ‚ÄúEffective R&D operations in the'80s: boosting the payoff from R&D.‚Äù
Research Management 25 (1):22‚Äì27.
Francis, Donald P. 2010. ‚ÄúSuccesses and failures: Worldwide vaccine development and
application.‚Äù Biologicals 38 (5):523‚Äì528.
GAO. 1999. ‚ÄúBEST PRACTICES: Better Management of Technology Development Can
Improve Weapon System Outcomes.‚Äù General Accounting Office.
www.gao.gov/products/NSIAD-99-162
Gouglas, Dimitrios, Le, Tung Thanh, Henderson, Klara, Kaloudis, Aristidis, Danielsen, Trygve,
Hammersland, Nicholas Caspersen, Robinson, James M., Heaton, Penny M., and
R√∏ttingen, John-Arne. 2018. ‚ÄúEstimating the cost of vaccine development against
epidemic infectious diseases: A cost minimisation study.‚Äù The Lancet Global Health
6(12):e1386-e1396.
Harapan, Harapan, Michie, Alice, Sasmono, R. Tajo, and Imrie, Allison. 2020. ‚ÄúDengue: A
minireview.‚Äù Viruses 12 (8):829.
KFF. 2020. The U.S. and Gavi, the Vaccine Alliance. Kaiser Family Foundation.
www.kff.org/global-health-policy/fact-sheet/the-u-s-and-gavi-the-vaccine-alliance/, June
2020.
Kim, Hyunsuh, Webster, Robert G., and Webby, Richard J. 2018. ‚ÄúInfluenza virus: Dealing with
a drifting and shifting pathogen.‚Äù Viral Immunology 31 (2):174‚Äì183.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Kristensen, Debra D, Lorenson, Tina, Bartholomew, Kate, and Villadiego, Shirley. 2016. ‚ÄúCan
thermostable vaccines help address cold-chain challenges? Results from stakeholder
interviews in six low- and middle-income countries.‚Äù Vaccine 34 (7):899‚Äì904.
Lambert, Paul-Henri, Ambrosino, Donna M., Andersen, Svein R., Baric, Ralph S., Black, Steven
B., Chen, Robert T., Dekker, Cornelia L., Didierlaurent, Arnaud M., Graham, Barney S.,
and Martin, Samantha D. 2020. ‚ÄúConsensus summary report for CEPI/BC March 12-13,
2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.‚Äù
Vaccine. doi: 10.1016/j.vaccine.2020.05.064 May 2020.
Laurens, Matthew B. 2018. ‚ÄúThe promise of a malaria vaccine‚ÄîAre we closer?‚Äù Annual Review
of Microbiology 72:273‚Äì292.
Ledley, F.D., McNamee, L.M., Uzdil, V., and Morgan, I.W. 2014. ‚ÄúWhy commercialization of
gene therapy stalled; Examining the life cycles of gene therapy technologies.‚Äù Gene
Therapy 21 (2):188‚Äì194.
Li, Jianping, Helal, Zeinab H., Karch, Christopher P., Mishra, Neha, Girshick, Theodore,
Garmendia, Antonio, Burkhard, Peter, and Khan, Mazhar I. 2018. ‚ÄúA self-adjuvanted
nanoparticle based vaccine against infectious bronchitis virus.‚Äù PloS ONE 13
(9):e0203771.
McNamee, Laura M. and Ledley, Fred D. 2012. ‚ÄúPatterns of technological innovation in
biotech.‚Äù Nature Biotechnology 30 (10):937‚Äì943.
McNamee, Laura M. and Ledley, Fred D. 2017. ‚ÄúModeling timelines for translational science in
cancer; The impact of technological maturation.‚Äù PLoS ONE 12 (3):e0174538.
McNamee, Laura M, Walsh, Michael Jay, and Ledley, Fred D. 2017. ‚ÄúTimelines of translational
science: From technology initiation to FDA approval.‚Äù PLoS ONE 12 (5):e0177371.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

McPherson, Clifton, Chubet, Richard, Holtz, Kathy, Honda-Okubo, Yoshikazu, Barnard, Dale,
Cox, Manon, and Petrovsky, Nikolai. 2016. ‚ÄúDevelopment of a SARS coronavirus
vaccine from recombinant spike protein plus delta inulin adjuvant.‚Äù Methods Mol Biol
1403:269-84.
Mehand, Massinissa Si, Al-Shorbaji, Farah, Millett, Piers, and Murgue, Bernadette. 2018. ‚ÄúThe
WHO R&D blueprint: 2018 review of emerging infectious diseases requiring urgent
research and development efforts.‚Äù Antiviral Research 159:63‚Äì67.
Modjarrad, Kayvon. 2016. ‚ÄúMERS-CoV vaccine candidates in development: The current
landscape.‚Äù Vaccine 34 (26):2982‚Äì2987.
Modjarrad, Kayvon, Roberts, Christine C., Mills, Kristin T., Castellano, Amy R., Paolino,
Kristopher, Muthumani, Kar, Reuschel, Emma L., Robb, Merlin L., Racine, Trina, and
Oh, Myoung-don. 2019. ‚ÄúSafety and immunogenicity of an anti-Middle East respiratory
syndrome coronavirus DNA vaccine: a Phase 1, open-label, single-arm, dose-escalation
trial.‚Äù The Lancet Infectious Diseases 19 (9):1013‚Äì1022.
NSF. 2018. Definitions of Research and Development: An Annotated Compilation of
Official Sources. www.nsf.gov/statistics/randdef/rd-definitions.pdf, March 2018.
NIH. 2019. Estimates of Funding for Various Research, Condition, and Disease Categories
(RCDC). exporter.nih.gov/ExPORTER_Catalog.aspx
NIH. 2020. Research portfolio online reporting tools (RePORTER), ExPORTER data catalog.
NVAC (National Vaccine Advisory Committee). 1997. ‚ÄúUnited States vaccine research: a
delicate fabric of public and private collaboration.‚Äù Pediatrics 100 (6):1015‚Äì1020.
O‚ÄôCallaghan, Kevin P, Blatz, Allison M., and Offit, Paul A. 2020. ‚ÄúDeveloping a SARS-CoV-2
vaccine at warp speed.‚Äù JAMA 2020;324(5):437-438.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Pardi, Norbert, Hogan, Michael J., Porter, Frederick W., and Weissman, Drew. 2018. ‚ÄúmRNA
vaccines‚Äîa new era in vaccinology.‚Äù Nature reviews Drug Discovery 17 (4): 261‚Äì279.
Plotkin, Stanley. 2014. ‚ÄúHistory of vaccination.‚Äù Proceedings of the National Academy of
Sciences 111 (34):12283‚Äì12287.
Plotkin, Stanley A. 2017. ‚ÄúVaccines for epidemic infections and the role of CEPI.‚Äù Human
Vaccines & Immunotherapeutics 13 (12):2755‚Äì2762.
Porter, Kevin R. and Raviprakash, Kanakatte. 2017. ‚ÄúDNA vaccine delivery and improved
immunogenicity.‚Äù Current Issues in Molecular Biology 22:129‚Äì138.
Pronker, Esther S., Weenen, Tamar C., Commandeur, Harry, Claassen, Eric H.J.H.M., and
Osterhaus, Albertus D.M,E. 2013. ‚ÄúRisk in vaccine research and development
quantified.‚Äù PloS ONE 8 (3):e57755. doi.org/10.1371/journal.pone.0057755.
Randolph, Haley E. and Barreiro, Luis B. 2020. ‚ÄúHerd immunity: Understanding COVID-19.‚Äù
Immunity 52 (5):737‚Äì741.
Rappuoli, Rino, Black, Steven, and Bloom, David E. 2019. ‚ÄúVaccines and global health: In
search of a sustainable model for vaccine development and delivery.‚Äù Science
Translational Medicine 11 (497):eaaw2888. doi: 10.1126/scitranslmed.aaw2888.
Safrit, Jeffrey T., Fast, Patricia E., Gieber, Lisa, Kuipers, Hester, Dean Hansi J., and Koff,
Wayne C. 2016. ‚ÄúStatus of vaccine research and development of vaccines for HIV-1.‚Äù
Vaccine 34 (26):2921‚Äì2925.
Schlake, Thomas, Thess, Andreas, Fotin-Mleczek, Mariola, and Kallen, Karl-Josef. 2012.
‚ÄúDeveloping mRNA-vaccine technologies.‚Äù RNA Biology 9 (11):1319‚Äì1330.
Stephens, Peter. 2014. ‚ÄúVaccine R&D: past performance is no guide to the future.‚Äù Vaccine 32
(19):2139‚Äì2142.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Tau, Noam, Yahav, Dafna, and Shepshelovich, Daniel. 2020. ‚ÄúPostmarketing safety of vaccines
approved by the US Food and Drug Administration: A cohort study.‚Äù Annals of Internal
Medicine. doi.org/10.7326/M20-2726
Thomas, Stephen J. and Barrett, Alan. 2020. ‚ÄúZika vaccine pre-clinical and clinical data review
with perspectives on the future development.‚Äù Human Vaccines &
Immunotherapeutics:1‚Äì13. doi: 10.1080/21645515.2020.1730657.
WHO. 2016. ‚ÄúAn R&D blueprint for action to prevent epidemics.‚Äù World Health Organization,
www.who.int/blueprint/what/improvingcoordination/workstream_5_document_on_financing.pdf?ua=1
WHO. 2018. ‚ÄúDengue vaccine: WHO position paper, September 2018‚Äîrecommendations.‚Äù
Vaccine 37:4848‚Äì4849.
WHO. 2019. ‚ÄúGlobal vaccine market report.‚Äù World Health Organization.
https://apps.who.int/iris/handle/10665/311278
WHO. 2020. ‚ÄúDRAFT landscape of COVID-19 candidate vaccines.‚Äù World Health
Organization. www.who.int/publications/m/item/draft-landscape-of-covid-19-candidatevaccines (Accessed July 31, 2020)
Zhu, Na, Zhang, Dingyu, Wang, Wenling, Li, Xingwang, Yang, Bo, Song, Jingdong, Zhao,
Xiang, Huang, Baoying, Shi, Weifeng, and Lu, Roujian. 2020. ‚ÄúA novel coronavirus
from patients with pneumonia in China, 2019.‚Äù New England Journal of Medicine.
382:727-733

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 1. Publications related to ten vaccine technologies used in candidate COVID-19
vaccines. A. Cumulative PMID from PubMed search over time. Data is shown on a logarithmic
scale. B. Maturation of research using the TIME model. Cumulative publications are shown as

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

symbols. Curves fitting the (exponentiated logistic) TIME model are shown as solid lines. The
calculated established points for these technologies are shown in the box. Curves exhibiting
exponential advance for technologies that have not yet reached an established point are shown as
dotted lines. Supplemental Figures 1‚Äì3 provide additional curve fits.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 2. NIH support for published research on ten vaccine technologies used in candidate
COVID-19 vaccines. A. Annual PMID, NIH-funded PMID, and the fraction of PMID receiving
NIH support for vaccine technologies. B. Annual project years and project costs associated with
NIH-funded PMID 2000‚Äì2019.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 3. NIH funding for published research on ten vaccine technologies and coronavirus
vaccines by activity category. A. Number of project years and project costs for research on ten
vaccine technologies by activity category 2000‚Äì2019. B. Number of project years and project
costs for research on coronavirus vaccines 2000‚Äì2019.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 4. NIH costs for published search on vaccines for HIV and selected zoonotic
pandemic threats (Coronavirus, Ebola, Zika, dengue) 2000‚Äì2019. A. Annual NIH costs
associated with published research on HIV vaccines compared to the cumulative total of research

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

on Coronavirus, Zika, Ebola, and dengue. B. Annual costs associated with published research on
Coronavirus, Zika, Ebola, and dengue. Symbols indicate years of major outbreaks as well as the
years of vaccine approval.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1. Publications in PubMed (PMID) and NIH funding associated with research on
technologies used in candidate COVID-19 vaccines as well as vaccine development for
selected epidemic threats.
PMID
(1960‚Äì2019)
Selected vaccine technologies
Synthetic Vaccines

3

Adjuvants, general

4

DNA (nucleic acid) vaccines

NIH-funded
Project Years Project Costs
PMID
2
1 (1980‚Äì2019) (2000‚Äì2019)
(1980‚Äì2019)

51530

8420 (16%)

16358

$17,171

21742

3935 (18%)

9755

$9,653

14347

2132 (15%)

5369

$5,642

7621

1464 (19%)

3742

$4,585

Live, Attenuated Virus

8147

1399 (17%)

3382

$4,053

Viral vector-based

1191

379 (32%)

1010

$1,651

Inactivated virus

5929

515 (8.7%)

1199

$1,469

TLR9 agonists (adjuvant)

1227

353 (29%)

1082

$1,096

mRNA vaccines

767

174 (23%)

534

$943

Virus-like particles

801

161 (20%)

418

$583

Nanoparticle-based

761

121 (16%)

334

$519

Vaccines against selected epidemic threats
HIV

5806

2024 (35%)

6684

$9,184

Coronavirus

2435

388 (16%)

625

$767

Ebola

450

115 (26%)

294

$639

Zika

375

135 (36%)

390

$555

Dengue

725

110 (15%)

231

$331

1 - Number of NIH-funded PMID and % of all PMID; Project Costs are in thousands of dollars
inflation adjusted to 2018; 3 - "Synthetic vaccines" is a MeSH term describing vaccines
incorporating recombinant protein antigens; 4 - Search performed for DNA vaccines included
many reports describing mRNA technologies.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.08.20187559; this version posted September 9, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

SUPPLEMENTAL FIGURES
Supplemental Figure 1 A‚ÄìG. Annual publications for seven vaccine technologies used in
candidate COVID-19 vaccines exhibiting logistic or exponential advance fit to the TIME
MODEL. The curve shown represents the first derivative of the exponentiated logistic function.
The established point represents the point of maximum deceleration of publication activity.
Supplemental Figure 2 A‚ÄìG. Cumulative publications for seven vaccine technologies used
in candidate COVID-19 vaccines exhibiting logistic or exponential advance fit to the TIME
MODEL. The curve shown represents exponentiated logistic function. Data is shown on a linear
scale.
Supplemental Figure 3 A‚ÄìG. Cumulative publications for seven vaccine technologies used
in candidate COVID-19 vaccines exhibiting logistic or exponential advance fit to the TIME
MODEL shown on log scale. The curve shown represents exponentiated logistic function. Data
is shown on a log scale, which illustrates the classic ‚ÄúS-curve‚Äù pattern of technological advance
seen in other fields of technology.

